1. Home
  2. GRFS vs BEP Comparison

GRFS vs BEP Comparison

Compare GRFS & BEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRFS
  • BEP
  • Stock Information
  • Founded
  • GRFS 1940
  • BEP 1999
  • Country
  • GRFS Spain
  • BEP Canada
  • Employees
  • GRFS N/A
  • BEP N/A
  • Industry
  • GRFS Biotechnology: Pharmaceutical Preparations
  • BEP Electric Utilities: Central
  • Sector
  • GRFS Health Care
  • BEP Utilities
  • Exchange
  • GRFS Nasdaq
  • BEP Nasdaq
  • Market Cap
  • GRFS 7.2B
  • BEP 7.3B
  • IPO Year
  • GRFS 2006
  • BEP N/A
  • Fundamental
  • Price
  • GRFS $10.13
  • BEP $24.88
  • Analyst Decision
  • GRFS Hold
  • BEP Buy
  • Analyst Count
  • GRFS 1
  • BEP 8
  • Target Price
  • GRFS $10.30
  • BEP $31.25
  • AVG Volume (30 Days)
  • GRFS 794.7K
  • BEP 469.2K
  • Earning Date
  • GRFS 01-01-0001
  • BEP 08-01-2025
  • Dividend Yield
  • GRFS 1.41%
  • BEP 5.92%
  • EPS Growth
  • GRFS 132.60
  • BEP N/A
  • EPS
  • GRFS 0.53
  • BEP N/A
  • Revenue
  • GRFS $8,744,226,659.00
  • BEP $6,174,000,000.00
  • Revenue This Year
  • GRFS $6.00
  • BEP $18.12
  • Revenue Next Year
  • GRFS $6.71
  • BEP $5.94
  • P/E Ratio
  • GRFS $24.82
  • BEP N/A
  • Revenue Growth
  • GRFS 9.32
  • BEP 12.75
  • 52 Week Low
  • GRFS $6.19
  • BEP $19.29
  • 52 Week High
  • GRFS $11.14
  • BEP $29.56
  • Technical
  • Relative Strength Index (RSI)
  • GRFS 52.17
  • BEP 44.45
  • Support Level
  • GRFS $9.57
  • BEP $24.48
  • Resistance Level
  • GRFS $9.99
  • BEP $25.99
  • Average True Range (ATR)
  • GRFS 0.18
  • BEP 0.47
  • MACD
  • GRFS -0.05
  • BEP 0.01
  • Stochastic Oscillator
  • GRFS 51.85
  • BEP 26.49

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

About BEP Brookfield Renewable Partners L.P.

Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners and Brookfield Renewable Corp.

Share on Social Networks: